|
1
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
DeSantis C, Ma J, Bryan L and Jemal A:
Breast cancer statistics, 2013. CA Cancer J Clin. 64:52–62. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kim H, Jang SM, Ahn H, Sim J, Yi K, Chung
Y, Han H, Rehman A, Chung MS, Jang K and Paik SS:
Clinicopathological significance of dual-specificity protein
phosphatase 4 expression in invasive ductal carcinoma of the
breast. J Breast Cancer. 18:1–7. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Valero V, Vrdoljak E, Xu B, Thomas E,
Gómez H, Manikhas A, Medina C, Li RK, Ro J, Bosserman L, et al:
Maintenance of clinical efficacy after dose reduction of
ixabepilone plus capecitabine in patients with anthracycline- and
taxane-resistant metastatic breast cancer: A retrospective analysis
of pooled data from 2 phase III randomized clinical trials. Clin
Breast Cancer. 12:240–246. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lotti F, Jarrar AM, Pai RK, Hitomi M,
Lathia J, Mace A, Gantt GA Jr, Sukhdeo K, DeVecchio J, Vasanji A,
et al: Chemotherapy activates cancer-associated fibroblasts to
maintain colorectal cancer-initiating cells by IL-17A. J Exp Med.
210:2851–2872. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tiago M, de Oliveira EM, Brohem CA,
Pennacchi PC, Paes RD, Haga RB, Campa A, de Moraes Barros SB,
Smalley KS and Maria-Engler SS: Fibroblasts protect melanoma cells
from the cytotoxic effects of doxorubicin. Tissue Eng Part A.
20:2412–2421. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang Y, Xu RC, Zhang XL, Niu XL, Qu Y, Li
LZ and Meng XY: Interleukin-8 secretion by ovarian cancer cells
increases anchorage-independent growth, proliferation, angiogenic
potential, adhesion and invasion. Cytokine. 59:145–155. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lee YS, Choi I, Ning Y, Kim NY,
Khatchadourian V, Yang D, Chung HK, Choi D, LaBonte MJ, Ladner RD,
et al: Interleukin-8 and its receptor CXCR2 in the tumour
microenvironment promote colon cancer growth, progression and
metastasis. Br J Cancer. 106:1833–1841. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Snoussi K, Mahfoudh W, Bouaouina N, Fekih
M, Khairi H, Helal AN and Chouchane L: Combined effects of IL-8 and
CXCR2 gene polymorphisms on breast cancer susceptibility and
aggressiveness. BMC Cancer. 10:2832010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Di Leo A, Curigliano G, Dieras V, Malorni
L, Sotiriou C, Swanton C, Thompson A, Tutt A and Piccart M: New
approaches for improving outcomes in breast cancer in Europe.
Breast. 24:321–330. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Conley SJ, Baker TL, Burnett JP, Theisen
RL, Lazarus D, Peters CG, Clouthier SG, Eliasof S and Wicha MS:
CRLX101, an investigational camptothecin-containing
nanoparticle-drug conjugate, targets cancer stem cells and impedes
resistance to antiangiogenic therapy in mouse models of breast
cancer. Breast Cancer Res Treat. 150:559–567. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yao YS, Qiu WS, Yao RY, Zhang Q, Zhuang
LK, Zhou F, Sun LB and Yue L: miR-141 confers docetaxel
chemoresistance of breast cancer cells via regulation of EIF4E
expression. Oncol Rep. 33:2504–2512. 2015.PubMed/NCBI
|
|
13
|
Arfaoui A, Douik H, Kablouti G, Chaaben
AB, Handiri N, Zid Z, Ouni N, Zouiouch F, Ayari F, Mamoughli T, et
al: Role of p53 Codon72 SNP in breast cancer risk and anthracycline
resistance. Anticancer Res. 35:1763–1769. 2015.PubMed/NCBI
|
|
14
|
Bezdenezhnykh N, Semesiuk N, Lykhova O,
Zhylchuk V and Kudryavets Y: Impact of stromal cell components of
tumor microenvironment on epithelial-mesenchymal transition in
breast cancer cells. Exp Oncol. 36:72–78. 2014.PubMed/NCBI
|
|
15
|
Mao Y, Keller ET, Garfield DH, Shen K and
Wang J: Stromal cells in tumor microenvironment and breast cancer.
Cancer Metastasis Rev. 32:303–315. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fu Z, Song P, Li D, Yi C, Chen H, Ruan S,
Shi Z, Xu W, Fu X and Zheng S: Cancer-associated fibroblasts from
invasive breast cancer have an attenuated capacity to secrete
collagens. Int J Oncol. 45:1479–1488. 2014.PubMed/NCBI
|
|
17
|
Amornsupak K, Insawang T, Thuwajit P,
O-Charoenrat P, Eccles SA and Thuwajit C: Cancer-associated
fibroblasts induce high mobility group box 1 and contribute to
resistance to doxorubicin in breast cancer cells. BMC Cancer.
14:9552014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Reis ST, Leite KR, Piovesan LF,
Pontes-Junior J, Viana NI, Abe DK, Crippa A, Moura CM, Adonias SP,
Srougi M and Dall'Oglio MF: Increased expression of MMP-9 and IL-8
are correlated with poor prognosis of bladder cancer. BMC Urol.
12:182012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Korantzis I, Kalogeras KT, Papaxoinis G,
Kotoula V, Koutras A, Soupos N, Papakostas P, Dionysopoulos D,
Samantas E, Christodoulou C, et al: Expression of angiogenic
markers in the peripheral blood of patients with advanced breast
cancer treated with weekly docetaxel. Anticancer Res. 32:4569–4580.
2012.PubMed/NCBI
|
|
20
|
Shi Z, Yang WM, Chen LP, Yang DH, Zhou Q,
Zhu J, Chen JJ, Huang RC, Chen ZS and Huang RP: Enhanced
chemosensitization in multidrug-resistant human breast cancer cells
by inhibition of IL-6 and IL-8 production. Breast Cancer Res Treat.
135:737–747. 2012. View Article : Google Scholar : PubMed/NCBI
|
